SecBot SecBot
8-K ·Filed Nov 2, 2026

QURE

uniQure N.V.
BULLISH
Impact 7/10
Horizonmonths Processed14d 17h ago SEC0001104659-26-120915
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The PDUFA date of May 1, 2027 sets a clear catalyst; watch for the Advisory Committee meeting date and outcome, which will be a key de-risking event. The confirmatory trial initiation by year-end 2026 is also a near-term milestone to monitor.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$22.97
T+0 close · Nov 2, 2026 · via day close
Latest settled
−0.78%
T+5 · $22.79 · next T+20 in 14d
Vs SPY
−0.86%
α at T+5
Latest observation
+0.82%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $22.97entry
  2. T+1 · 14d ago +3.92%α +3.62% · $23.87
  3. T+5 · 8d ago −0.78%α −0.86% · $22.79
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

uniQure announced that the FDA has accepted for review its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease, under the Accelerated Approval pathway with Priority Review and a PDUFA target action date of May 1, 2027. The FDA is tentatively planning an Advisory Committee meeting, and the company has aligned with the FDA on a confirmatory study design. This is a significant regulatory milestone for a first-in-class therapy in an area with no approved disease-modifying treatments.

Key Facts

  • FDA accepted BLA for ifezuntirgene inilparvovec for Huntington's disease under Accelerated Approval pathway
  • Priority Review granted with PDUFA target action date of May 1, 2027
  • FDA tentatively planning an Advisory Committee meeting
  • BLA supported by 36-month Phase I/II data vs propensity score-matched external control (Enroll-HD database)
  • Confirmatory study design aligned with FDA: randomized, ~200 patients, 2:1 ratio, TFC primary endpoint at 36 months
  • Patient screening in the U.S. expected to begin by end of 2026
  • Ifezuntirgene inilparvovec is the first HD therapy to receive Breakthrough Therapy and RMAT designations, also holds Fast Track designation
  • If approved, would be the world's first disease-modifying treatment for Huntington's disease

Financial Impact

No financial figures disclosed; potential approval would open a market of approximately 75,000 patients in the U.S., EU, and UK with no current disease-modifying therapies

revenue

Risk Factors

  • FDA may hold an Advisory Committee meeting, which introduces uncertainty and potential for negative recommendation
  • Accelerated approval is not guaranteed; FDA may conclude Phase I/II data or confirmatory trial data are insufficient
  • Confirmatory study enrollment and completion risks, including cost and timeline
  • Post-approval requirements could be costly or difficult to satisfy
  • Competition from other HD therapies in development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-120915
Document: tm2628699d1_ex99-1.htm0001104659-26-120915
Document: 0001104659-26-120915-index-headers.html0001104659-26-120915
Document: 0001104659-26-120915-index.html0001104659-26-120915
Document: 0001104659-26-120915.txt0001104659-26-120915

Track record

38 reports on QURE

Performance horizon

5 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.

Filters
  1. Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 7/10 No price data
  3. Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 7/10 Viewing Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  5. Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  6. Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
  8. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
  9. Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens in 8h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026